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OBJECTIVE—To compare the efﬁcacy and safety of duloxetine and amitriptyline in painful
diabetic neuropathy (PDN).
RESEARCH DESIGN AND METHODS—In this randomized, double-blind, cross-over,
active-control trial, 58 patients received amitriptyline and duloxetine orally once daily at bed-
time, each for 6 weeks with optional dose uptitration fortnightly. Single-blinded placebo wash-
out was given for 2 weeks between the two treatments and a single-blinded placebo run-out
phase of 4 weeks was given at the end of the treatment period. Pain relief was measured by the
patient’sglobalassessmentofefﬁcacy,usingavisualanalogscale(0–100)asaprimaryendpoint,
and overall improvement and adverse events were assessed as secondary outcome measures.
Median pain score reductions of .50%, 25–50%, and ,25% were considered good, moderate,
and mild responses, respectively.
RESULTS—There wasasigniﬁcant improvement inpainwith both treatmentscompared with
their baseline values (P , 0.001 for both). Good, moderate, and mild pain relief was achieved in
55, 24, and 15% of patients, respectively, on amitriptyline and 59, 21, and 9% of patients,
respectively, on duloxetine. There were no signiﬁcant differences in various other outcome
measures between the groups. Of the reported adverse events, dry mouth was signiﬁcantlymore
common with amitriptyline than duloxetine (55 vs. 24%; P , 0.01). Although, numerically,
more patients preferred duloxetine, overall this was not statistically signiﬁcant (48 vs. 36%;
P =0 . 1 8 ) .
CONCLUSIONS—Both duloxetine and amitriptyline demonstrated similar efﬁcacy in PDN.
Alarge,multicentricclinicaltrialinotherpopulationscouldpossiblydemonstratethesuperiority
of either drug.
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T
he management of painful diabetic
neuropathy (PDN) includes inten-
sive glycemic control and drugs for
pain relief. The American Diabetes Asso-
ciation recommends amitriptyline, a tri-
cyclic antidepressant, as the ﬁrst choice;
however, titration to higher doses is
limited by its anticholinergic adverse ef-
fects (1). The selective serotonin norepi-
nephrine reuptake inhibitor, duloxetine,
is approved by the Food and Drug
Administration for the treatment of
PDN. It attenuates persistent pain mech-
anisms, including the central sensitiza-
tion and hyperexcitability of the spinal
and supraspinal pain-transmitting path-
ways. Duloxetine has been evaluated in
placebo-controlled trials for a variety of
chronic pain, including PDN (2–6). It
not only relieves pain but also improves
functionalityandqualityoflifeinpatients
with PDN. An extensive search of litera-
turedidnotrevealanyhead-to-headcom-
parison of duloxetine with amitriptyline,
an established ﬁrst-line therapy for PDN
(1). Thus, the current study was planned
to compare the efﬁcacy and safety of du-
loxetine with amitriptyline in PDN.
RESEARCH DESIGN AND
METHODS—Patients of either sex
with type 2 diabetes, aged between 18
and75years,whowereonstableglucose-
lowering medications during the preced-
ing month and who had PDN for at least
1 month were considered for the study.
Patients who had a pain score of .50%,
as assessed by visual analog scale (VAS),
were enrolled in the study. Those previ-
ously exposed to medications for PDN,
regardless of dose and duration, were
consideredafter2weeksofplacebowash-
out in a single-blind manner. The study
was initiated after approval by the institu-
tional ethics committee and was con-
ducted following the principles of the
Declaration of Helsinki. Written informed
consent was obtained from each subject
prior to enrollment.
PDN was conﬁrmed by 1) the pa-
tient’s medical history, 2) a diabetic neu-
ropathy symptom (DNS) score of .1
point (7), 3) a diabetic neuropathy exam-
ination(DNE)scoreof.3point s( 8),4)a
modiﬁed neuropathy symptom score
(NSS) (9,10), and 5) increased thresholds
on the vibration perception test and
monoﬁlament test. Patients were ex-
cluded if they had any clinically signiﬁ-
cant or unstable medical or psychiatric
illnesses. Patients with other causes of
neuropathy; renal dysfunction (serum
creatinine .132 mmol/L); liver disease
(alanine aminotransferase and aspartate
aminotransferase more than three time
times the normal level); epilepsy; psychi-
atric illness; uncontrolled hypertension;
malignancy; substance abuse; those tak-
ing anticonvulsants, antidepressants, lo-
cal anesthetics, or opioids; those who
were pregnant; lactating women; or those
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ORIGINAL ARTICLEbeing treated with any investigational
drug within the last 30 days were ex-
cluded from the study.
A 14-week, randomized (computer-
generatedrandomizationofblocksoffour),
double-blind, cross-over, active-control
with optional dose titration, equivalence
clinical trial was conducted. All patients
underwentaninitial2-weekrun-inperiod
in order to achieve a baseline state (during
which the patients were withdrawn from
any existing medication for PDN), fol-
lowed by 6 weeks of treatment with each
drug and a washout period of 2 weeks
between the two therapies. At the end of
14 weeks, patients entered a 4-week run-
outphase,duringwhichplaceboresponse
was evaluated in a single-blind manner.
Threedoseseachofamitriptyline(10,
25, or 50 mg once daily at bed time) and
duloxetine (20, 40, or 60 mg once daily
at bed time) were used in the study.
Wockhardt Limited (Mumbai, India)
andSunpharmaceuticalIndustriesLimited
(Mumbai, India) provided amitriptyline
and duloxetine, respectively, as free sam-
ples. Treatment was started with the low-
est dose of either drug, with fortnightly
assessments with optional uptitration.
The primary end point of the study
was the reduction in the median pain
score from baseline, as assessed by the
patient’s global assessment of efﬁcacy by
the VAS (0–100 points). Secondary end
points included the assessment of pain by
theshort-formMcGillPainQuestionnaire
(11);an11-pointLikertscaleforpain(0=
nopainand10=excruciatingpain);over-
all improvement by DNE score, DNS
score, modiﬁed NSS, and the 24-point
Hamilton Rating Scale for Depression
(12); change in sleep pattern (increased,
unchanged, or decreased); and patient
self-evaluation of overall change on the
basis of a 7-point patient global impres-
sion of change (PGIC) scale. Treatment-
emergent adverse events (TEAEs) were
assessed by clinical and laboratory evalu-
ation of fasting and postprandial plasma
glucose, A1C levels, lipid proﬁle, urea,
creatinine, aspartate aminotransferase/
alanine aminotransferase, and alkaline
phosphatase. The patient’sp r e f e r e n c eo f
treatment was assessed by direct ques-
tionnaire. Demographic characteristics
were noted and all the parameters were
measured before and after treatment
with both drugs and compared.
Uptitrationwasdoneafterassessment
of the therapeutic response and tolerabil-
ity by the above-mentioned scores. Blind-
ing and randomization were carried out
by an independent person unrelated to
the study. The drug packets were admin-
isteredtopatientsseriallyaccordingtothe
patient’s reporting sequence. A median
pain score reduction on the basis of the
VAS of .50%, between 25 and 50%, and
,25% were considered as good, moder-
ate, and mild responses, respectively.
Overall improvement in pain intensity of
$30 and $50% also was assessed. As-
sessments for depression and change in
sleep pattern were performed at the be-
ginningandendofeachofthetreatments,
PGIC was assessed at the end of each
treatment period, and patient preference
of treatment was carried out fortnightly
after beginning the second treatment,
whereas all other assessments were per-
formed at each of the 2-weekly follow-
up visits. The investigator administered
the drug and performed assessment for
the efﬁcacy and safety at each visit and
was accessible by telephone to all patients
throughout the study. No additionaldose
escalation was carried out in the case of
appearance ofadverseevents,lack ofben-
eﬁt with the initial two doses (no beneﬁt
on patient VAS), patient’s satisfaction
with pain relief, the highest dose was
reached, or patient’s noncompliance. Pa-
tients were reminded by telephone calls
for the due visits and also were traced for
missed visits. In case of a missed visit, the
patient was given the scheduled dose if
he/she turned up during the stipulated
timeof2weeksorelsetheplacebowashout
was given and the next scheduled drug
was started. Patients were not allowed
any pain medication other than up to
3gperdayparacetamolasarescuemed-
ication during the trial period, except
24 h prior to assessment. Compliance
was assessed by direct questioning
and pill counting. Success of blinding
was assessed by the accuracy of the
physician’s prediction at the end of the
study.
Statistical analysis
The sample size calculation was based on
the means and SDs observed for pain
scores in previous trials of duloxetine
versus placebo and amitriptyline versus
placebo in PDN. The efﬁcacy of both
drugs was estimated to be 70%. To prove
that there is no difference in efﬁcacy
between the two treatments, with two-
sided signiﬁcance levels of 2.5% and
power of 80%, a within-subject SD of
20%, and a maximum-allowable differ-
ence of 10%, the total number of patients
to be included was 44. Because of its
cross-over design, with 40% noncompli-
ance and loss to follow-up, we decided to
include a total of 60 patients in the study.
The primary and secondary efﬁcacy anal-
yses were performed on the intention-to-
treat population, deﬁned as patients who
received at least one dose of randomized
study medication and had at least one
postbaseline efﬁcacy assessment. Values
are expressed as means 6 SD, median
Table 1—Baseline demographic parameters of patients who completed the study
Characteristics Values
Age (years) 52.5 (48.2–62)
Sex
Male 27 (47)
Female 31 (53)
Height (cm) 158.8 (153.6–166.7)
Weight (kg) 69 (64.0–77.7)
Waist circumference (cm) 93.1 (88.2–99.1)
BMI (kg/m
2)2 6 . 8 ( 2 4 . 7 –29.3)
Duration of diabetes (years) 7 (2–12)
Duration of pain (months) 18 (6–36)
Site of pain
Foot 45 (78)
Foot and hand 13 (22)
Hypertension 43 (74)
Vibration perception threshold score 25 (14–33.8)
DNS (.1 point abnormal) 58 (100)
DNE (.3 points abnormal) 58 (100)
NSS (1–9) 7 6 1.8
A1C (%) 8.2 6 1.7
Data are median (IQR), means 6 SD, or n (%). n = 58 patients.
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Kaur and Associateswith interquartile range (IQR), and num-
bers and percentages.
The median pain scores, the patient
VAS, the Likert pain scale, and the McGill
Pain Questionnaire were compared using
the Wilcoxon matched-pair test. In addi-
tion, data from all visits were compared
with baseline scores using the Friedman
test for intragroup comparison. PGICwas
compared by the McNemar-Bowker test.
The Hamilton Depression Rating Scale,
altered sleep pattern, percentage of pa-
tients showing improvement, treatment
preference, and incidence of adverse
events were compared using the x
2 test
or Fisher exact test. Baseline parameters
were compared by the Student paired or
unpaired t test, x
2 test, or Fisher exact
test. A P value ,0.05 was considered sig-
niﬁcant. SPSS (version 12.0) was used to
perform analysis.
RESULTS—The study was conducted
between March 2009 and April 2010.
Patient demography, clinical character-
istics, and disposition through the study
period are summarized in Table 1 and
Fig. 1, respectively. Of 203 patients
screened, 86 were found to be eligible
and 65 patients reported for randomiza-
tionfollowingtherun-inperiod.Ofatotal
of 58 patients, 53 (91%) completed the
study with .80% compliance. The rea-
sons for noncompliance included fre-
quent follow-up visits and long distance
from hometo thehospital.Scores atbase-
line both before and after the crossover
were similar in the two groups, and,
thus, the data were pooled. No patient
suffered from depression as per the Ham-
ilton Depression Rating Scale. Previously
tried treatments for neuropathic pain in-
cluded the use of pregabalin in 20%, am-
itriptyline in 8%, and duloxetine and
gabapentin in 2% of patients each.
With duloxetine, 59% (n = 34) of pa-
tients showed good improvement, 22%
(n = 13) showed moderate improvement,
and 9% (n =5 )s h o w e dm i l di m p r o v e -
ment. With amitriptyline, 55% (n = 32)
of patients showed good improvement,
24% (n = 14) showed moderate improve-
ment, and 16% (n =9 )s h o w e dm i l di m -
provement (Fig. 2).
Overall pain relief of .30% was ob-
served in 64 and 62% of patients with
duloxetine and amitriptyline, respec-
tively, and .50% improvement was seen
in 59 and 55% of patients with duloxetine
and amitriptyline, respectively. No signif-
icantdifferenceintheefﬁcacybetweenthe
two treatments was observed on other
scales as well (McGill Pain Question-
naire and Likert scale), and both drugs
signiﬁcantly relieved pain at 6 weeks
(P , 0.001 for both). Signiﬁcant im-
provementinsleepandoverallwellbeing
wasobservedwithbothdrugs(P,0.001
for both).
Of the total study population 5, 14,
and 30% preferred 20, 40, and 60 mg
duloxetine, respectively, whereas 5, 22,
and 9% preferred 10, 25, and 50 mg of
amitriptyline, respectively, based on pain
relief and tolerability. In the whole
cohort, 48% (n = 28) of patients preferred
duloxetine and 36% (n = 21) of patients
preferred amitriptyline, but it was not sta-
tisticallysigniﬁcant(P=0.18).Inaddition,
16% of patients had no preference, out of
which 9% were equally satisﬁed and 7%
were equally dissatisﬁed with either treat-
mentoptions.Forty-eightpercent(n=28)
of patients with amitriptyline and 65%
(n = 38) with duloxetine were uptitrated
to their highest doses of 50 and 60 mg,
respectively. Signiﬁcantly more patients
preferred a higher dose of duloxetine
Figure 1—CONSORT statement.
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Amitriptyline or duloxetine in PDN(n=17)comparedwithamitriptyline(n=5;
P , 0.02).
Table 2 depicts TEAEs with the two
drugs. The events were similar between
amitriptyline (n = 111) and duloxetine
(n = 112). The number of mild TEAEs
with duloxetine was higher compared
with amitriptyline (P , 0.02), whereas
the number of moderate to severe TEAEs,
limitingdoseuptitrationandrequiringin-
terventionor discontinuationof thedrug,
was higher with amitriptyline (P , 0.01).
Moderate to severe TEAEs were more
common with amitriptyline compared
with duloxetine (51 vs. 24% of patients;
P , 0.01). Of all the events, dry mouth
was signiﬁcantly more common with am-
itriptyline (P , 0.01). The more common
adverse events reported with duloxetine
were constipation and somnolence. No
signiﬁcant change in weight was noticed
with either therapy. The mean A1C levels
improved from 8.2 to 7.8% (P , 0.01).
The fasting and postprandial plasma
glucose levels, lipid proﬁle, and renal
and liver function tests did not change
signiﬁcantly with either of the drugs
over the treatment period. The investiga-
tor was able to identify the prescribed
drug correctly in 34% of the patients at
therun-outphase.ThemedianVAS(IQR)
score increased from 26 (10–40) to 40
(20–54) at the end of run-out phase (P ,
0.001), and the average run-out duration
was 21 6 12 days.
CONCLUSIONS—The current study
compared the efﬁcacy and safety of
duloxetine with amitriptyline head to
head in patients with PDN. Both drugs
demonstratedcomparableefﬁcacyandsafety
as per the established pain-rating scales for
PDN.Although,numerically,morepatients
preferredduloxetineoveramitriptyline,this
did not reach the level of signiﬁcance.
In the present trial, both duloxetine
and amitriptyline demonstrated similar
efﬁcacy (.30% pain relief). More than
50% improvement in pain score was ob-
served in 59% of patients with duloxetine,
compared with 49–52% in various
placebo-controlled trials (4,5,13), and
55% with amitriptyline, compared with
51–58% in other placebo-controlled and
active-control trials (14–16). Improve-
ment in pain was signiﬁcant with both
drugs as per patient assessment by the
VAS, the 11-point Likert scale, and the
McGillPainQuestionnaire.Theseﬁndings
are in concordance with previous stud-
ies (17,18) where pain evaluation was
conﬁrmed by similar well-established
pain-evaluation scores. In addition, neu-
ropathy status was evaluated using well-
establishedscalesliketheDNSscore,DNE
score,andmodiﬁedNSS,whichalsodem-
onstrated signiﬁcant improvement. The
pain scores demonstrated pain resurgence
during the washout and run-out phase
(Fig. 2). This suggests that the drugs do
not affect the basic pathophysiology of
PDN; however, it also is too short a dura-
tion of therapy to comment on the same.
There was comparable improvement in
sleep with both drugs, as per the sleep
score. There was a signiﬁcant improve-
ment in A1C over the trial period, and
thus the reduction in cumulative glycemic
burden can be expected to contribute to
the pain relief and may have a confound-
ing effect on the efﬁcacy assessment
(13,19). However, this is negated because
of the cross-over study design and dem-
onstration of pain resurgence during the
washout and run-out phases.
The various published placebo-
controlledstudiesonduloxetinefortreat-
ing PDN have parallel designs for efﬁcacy
Figure 2—Median VAS pain scores of patients.
Table 2—Adverse events observed
Adverse events Duloxetine Amitriptyline P
Somnolence 18 (31) 21 (36) 0.89
Dry mouth 14 (24) 32 (55) ,0.001
Constipation 22 (37) 10 (17) 0.06
Lethargy 14 (24) 19 (33) 0.30
Insomnia 9 (15) 6 (10) 0.71
Uneasiness 11 (19) 6 (10) 0.40
Dizziness 7 (12) 8 (14) 0.86
Nausea 6 (10) 3 (5) 0.58
Anorexia 5 (8) 1 (2) 0.25
Headache 4 (7) 3 (5) 0.78
Pain abdomen 1 (2) 1 (2) 0.95
Itching 1 (2) 1 (2) 0.95
Total adverse events (n) 112 111
Mild events* 98 82 ,0.02
Moderate to severe events† 14 29 ,0.01
Data are n (%).n = 58 in each group. *Mild: not requiring any intervention or discontinuation. †Moderate to
severe: limiting dose uptitration, requiring intervention or discontinuation of the drug.
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study has a cross-over design and dose
titration was gradual, from a low 20–60
mg daily compared with trials evaluating
20–120 mg ﬁxed daily doses. It was con-
sidered appropriate to plan two weekly
evaluations because previous trials have
demonstrated efﬁcacy within 2 weeks of
the onset of therapy. Therefore, the study
was planned to be of shorter duration
(i.e., 6 weeks of active drug therapy com-
pared with a duration of 12–52 weeks, as
in other trials [5,21]). The most preferred
effective doses were 60 mg duloxetine
and 25 mg amitriptyline, which are lower
than the recommended dose range of 60–
120 mg and 25–150 mg for duloxetine
and amitriptyline, respectively (1,22,23).
Even at these doses, moderate pain relief
was achieved, and as conferred in the pre-
vious studies the lower doses of amitripty-
line are effective because of the possible
lower body size and weight of the Indian
population (17,18,24).
The overall safety assessment was
comparable for both duloxetine and
amitriptyline, except for the intensity of
adverse events. Dose escalation with
amitriptyline was limited by its TEAEs
(especially dry mouth). There were no
signiﬁcant differences in the laboratory
parametersbeforeandafterthetreatment,
suggesting the safety of both drugs. Ad-
verse events with both drugs were compa-
rable with those reported in the previous
studies (5,13,14,17,20,21,25).
Thestrengthsofthe study include the
randomized, active-control, cross-over,
double-blind, and adequately powered
design with a good compliance rate. In
addition, use of multiple established rat-
ing scales for evaluating neuropathy as
well as efﬁcacy and gradual dose uptitra-
tionenhancedtheoutcomeevaluation.The
study was limited by the lack of a placebo
arm, which might have enhanced the
sensitivity in pain relief with the test drug
inPDN.However,theplacebousedduring
the run-outphase ina single-blindmanner
led to the reappearance of pain in most of
the patients necessitating intervention.
In conclusion, both amitriptyline and
duloxetine demonstrated comparable ef-
ﬁcacy, safety, and tolerability in the man-
agement of PDN. A similar head-to-head
comparison in a multicentric clinical trial
using a larger sample size could possibly
demonstrate the superiority of either drug.
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